share_log

Allarity Therapeutics | SCHEDULE 13G: Others

Allarity Therapeutics | SCHEDULE 13G: Others

Allarity Therapeutics | SCHEDULE 13G:其他
美股SEC公告 ·  08/30 06:01

牛牛AI助理已提取核心訊息

Olmsted Investments LLC has filed a Schedule 13G with the Securities and Exchange Commission on August 19, 2024, indicating a significant ownership stake in Allarity Therapeutics, Inc. The Utah-based investment firm reported beneficial ownership of 10,000 shares of Allarity's Series A Convertible Redeemable Preferred Stock, representing 28.6% of the class. The filing, which is a requirement for parties owning more than 5% of a company's stock, specifies that Olmsted Investments LLC has sole voting and dispositive power over the shares. The address of Allarity Therapeutics' principal executive offices is listed as 24 School St., 2nd Floor, Boston, Massachusetts, 02108. Olmsted Investments LLC has certified that the acquisition of these shares is not for the purpose of changing or influencing the control of Allarity Therapeutics, nor is it connected with any transaction that has such purpose or effect.
Olmsted Investments LLC has filed a Schedule 13G with the Securities and Exchange Commission on August 19, 2024, indicating a significant ownership stake in Allarity Therapeutics, Inc. The Utah-based investment firm reported beneficial ownership of 10,000 shares of Allarity's Series A Convertible Redeemable Preferred Stock, representing 28.6% of the class. The filing, which is a requirement for parties owning more than 5% of a company's stock, specifies that Olmsted Investments LLC has sole voting and dispositive power over the shares. The address of Allarity Therapeutics' principal executive offices is listed as 24 School St., 2nd Floor, Boston, Massachusetts, 02108. Olmsted Investments LLC has certified that the acquisition of these shares is not for the purpose of changing or influencing the control of Allarity Therapeutics, nor is it connected with any transaction that has such purpose or effect.
Olmsted Investments LLC已在2024年8月19日向證券交易委員會提交了13G表,表明在Allarity Therapeutics, Inc.擁有重要的所有權。這家總部位於猶他州的投資公司報告稱擁有Allarity的A類可轉換可贖回優先股10,000股,佔該類股票的28.6%。該提交的要求來自於持有公司5%以上股份的一方,規定Olmsted Investments LLC對這些股份擁有獨立的投票和實際控制權。Allarity Therapeutics的主要執行辦公室地址列爲馬薩諸塞州波士頓市02108郵政編碼的School St.24號2樓。Olmsted Investments LLC已確認其收購這些股份並非出於改變或影響Allarity Therapeutics 控制權的目的,也與具有上述目的或效果的任何交易無關。
Olmsted Investments LLC已在2024年8月19日向證券交易委員會提交了13G表,表明在Allarity Therapeutics, Inc.擁有重要的所有權。這家總部位於猶他州的投資公司報告稱擁有Allarity的A類可轉換可贖回優先股10,000股,佔該類股票的28.6%。該提交的要求來自於持有公司5%以上股份的一方,規定Olmsted Investments LLC對這些股份擁有獨立的投票和實際控制權。Allarity Therapeutics的主要執行辦公室地址列爲馬薩諸塞州波士頓市02108郵政編碼的School St.24號2樓。Olmsted Investments LLC已確認其收購這些股份並非出於改變或影響Allarity Therapeutics 控制權的目的,也與具有上述目的或效果的任何交易無關。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。